Blog
RSS FeedPosted by Michael Wonder on 22 Apr 2016
Germany mulls limiting prices drug firms can charge to health system
22 April 2016 - The move would curtail a lucrative, one-year amnesty from the country’s otherwise strict price controls. ...
Posted by Michael Wonder on 06 Apr 2016
Genvoya in HIV: positive effects predominate in some adults, negative effects in others says Germany's IQWiG
1 April 2016 - The fixed-dose combination of the drugs elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide has been available under the ...
Posted by Michael Wonder on 04 Apr 2016
Efmoroctocog alfa for haemophilia A: IQWIG says an additional benefit is not proven
1 April 2016 - Efmoroctocog alfa (trade name: Elocta) has been approved since November 2015 for people with type A haemophilia. ...
Posted by Michael Wonder on 02 Apr 2016
HIV-positive children and adolescents: additional benefit of rilpivirine not proven
1 April 2016 - Under the trade name Edurant, rilpivirine hydrochloride as single agent has been approved already since 2011 for ...
Posted by Michael Wonder on 19 Mar 2016
Addendum on regorafenib in metastatic colorectal cancer: added benefit no longer proven
17 March 2016 - The drug manufacturer presented further analyses; the additional disadvantages outweigh the survival advantage. ...
Posted by Michael Wonder on 19 Mar 2016
Dabrafenib/trametinib: considerable added benefit for men with advanced melanoma
17 March 2016 - Study data subsequently submitted allow quantification / still major added benefit for women. ...
Posted by Michael Wonder on 16 Mar 2016
Cobimetinib in advanced melanoma with BRAF V600 mutation: little additional value says Germany's IQWiG
15 March 2016 - TheIQWiG found more positive and negative patient-relevant outcomes, which tend to cancel each other. There ...
Posted by Michael Wonder on 15 Mar 2016
Secukinumab for active ankylosing spondylitis or psoriatic arthritis; no additional clinical benefit says Germany's IQWiG
15 March 2016 - Since Novartis cited no adequate studies, an additional benefit of secukinumab versus the appropriate comparator therapies has ...
Posted by Michael Wonder on 01 Mar 2016
Fingolimod in multiple sclerosis: no evidence of additional benefits in the new application
1 March 2016 - This assessement was about patients with highly active relapsing-remitting multiple sclerosis, on a full and adequate course ...
Posted by Michael Wonder on 01 Mar 2016
Aflibercept in myopic choroidal neovascularisation: additional benefits not covered
1 March 2016 - Since the manufacturer provides no adequate studies, an additional benefit of aflibercept versus the appropriate comparator therapy ...
Posted by Michael Wonder on 15 Feb 2016
Alirocumab hypercholesterolemia or mixed dyslipidaemia: additional benefits not covered says IQWiG
15 February 2016 - An additional benefit compared to the appropriate comparator therapies has not been established for this substance because ...
Posted by Michael Wonder on 16 Jan 2016
Aclidinium bromide in COPD: evidence of significant additional value in certain patients
15 January 2016 - With reference to new scientific evidence, the manufacturer requested a reassessment and submitted a new dossier. ...
Posted by Michael Wonder on 14 Jan 2016
Regorafenib in metastatic colorectal cancer: still only a hint of a minor additional benefit
4 January 2016 - After the expiry of the decision it made in 2014, the IQWIG has the reached same ...
Posted by Michael Wonder on 13 Jan 2016
Nivolumab in melanoma: data subsequently submitted improve assessment result
7 January 2016 - In an addendum, the IQWiG assessed study data submitted by BMS. In treatment-naive patients whose tumour is ...
Posted by Michael Wonder on 12 Jan 2016
Pomalidomide in multiple myeloma: no sign of an additional clinical benefit
4 January 2016 - The IQWiG examined whether pomalidomide offers an added benefit over the appropriate comparator therapy. No such added ...